Biological Industries is now part of the Sartorius group. Click here for more

MSC NutriStem® XF Medium

  • Defined, xeno-free, serum-free medium

  • Designed for optimal growth and expansion of human MSCs

  • Customizable formulation

  • Custom scale-up services available

  • Scientific and regulatory support

  • Drug Master Files available

Name SKU Size
MSC NutriStem® XF Medium, without Phenol Red (Basal Medium + Supplement) 05-202-1A-KT 500 mL
MSC NutriStem® XF Medium (Basal Medium + Supplement) 05-200-1A-KT 500 mL
MSC NutriStem® XF Basal Medium 05-200-1A 500 mL
MSC NutriStem® XF Basal Medium, without Phenol Red 05-202-1A 500 mL
MSC NutriStem® XF Supplement Mix 05-201-1U 3 mL



Product Overview:

Faster growth rates and stronger cell yields

MSC NutriStem® XF Medium is a defined, serum-free, xeno-free culture medium designed for optimal growth and expansion of human mesenchymal stem/stromal cells (hMSC) derived from a variety of sources, including bone marrow (BM-MSC), adipose tissue (AT-MSC) and umbilical cord matrix (UC-MSC). MSC NutriStem® XF Medium supports long-term growth of hMSC while maintaining their self-renewal and multi-lineage differentiation potential.

hMSCs cultured in MSC NutriStem XF Medium show superior proliferation and self-renewal potential in comparison to serum-containing media and other commercial serum-free media.  In addition, hMSCs maintain their proper fibroblast-like cell morphology, tri-lineage differentiation potential, and demonstrate normal hMSC marker profiles, and karyotypic stability over long-term culture. 

Key advantages

  • Serum-free, xeno-free, defined culture system
  • Superior cell growth compared to serum-containing media
  • Supports long-term growth and self-renewal of hMSCs from multiple sources
  • Consistent, reliable MSC cultures
  • Suitable for the harvest of high quality exosomes (EVs) for future clinical applications
  • Eliminates the need to spend time and money pre-qualifying FBS lots
  • Manufactured under cGMP
  • FDA Drug Master File (DMF) available

Cells cultured in serum-containing medium do not require an adaptation phase when transitioning to serum-free MSC NutriStem® XF Medium.

hMSC-BM were cultured in MSC NutriStem® XF

Figure: NutriStem® MSC XF Medium promotes superior proliferation and expansion of hMSCs over time as compared to other serum-free and serum-containing media.

Sample Data

Initial isolation

Figure: Human mesenchymal stem cells were initially isolated from Wharton's jelly (left image) and placenta (right image) using MSC NutriStem® XF on pre-coated plates with MSC Attachment Solution (cat. no. 05-752-1). High number of hMSC was obtained.


Figure: MSC NutriStem® XF promotes excellent proliferation of hMSC from a variety of sources while maintaining normal fibroblast-like, spindle shape cell morphology.


Self-renewal potential

Figure: hMSC-BM and hMSC-AT were expanded in MSC NutriStem® XF for 3-5 passages prior to 14 days of CFU-F assay. Colonies were stained with 0.5% crystal violet (x100). The cells maintain their self-renewal potential.

Differentiation potential

Figure: hMSC-BM (top panel) and hMSC-AT (bottom panel) expanded in MSC NutriStem® XF for 3-5 passages prior to trilineage differentiation. Representative images of stained adipocytes (Oil Red O), osteocytes (Alizarin Red) and chondrocytes (Alcian Blue). The cells maintain their multilineage differentiation potential.



Form Liquid
Brand NutriStem®
Quality Control MSC NutriStem® XF Medium is application-tested and validated for optimal maintenance and expansion of undifferentiated hMSCs, while maintaining their multi-lineage differentiation potential.
Specifications The complete mesenchymal stem cell culture media consists of two components: MSC NutriStem® XF Basal Medium (05-200-1) and MSC NutriStem® XF Supplement Mix (05-201-1).
Instructions for Use

Storage and Stability

  • MSC NutriStem® XF Basal Medium (05-200-1) should be stored at 2 to 8°C. 
  • MSC NutriStem® XF Supplement Mix (05-201-1) should be stored at -20°C. Avoid freeze/thaw cycles.
  • The complete MSC NutriStem® XF Medium is stable at 2 to 8°C for up to 30 days.
  • Avoid exposure to light.  

Medium Preparation

  • Thaw frozen MSC NutriStem® XF Supplement Mix at at 2 to 8°C or room temperature.
  • MSC NutriStem® XF Basal Medium contains L-glutmine.
  • To prepare 100 mL of complete medium:  aseptically add 0.6 mL of MSC NutriStem® XF Supplement Mix to 100 mL of MSC NutriStem® XF Basal Medium.
  • To prepare 500 mL of complete medium:  aseptically add 3 mL of MSC NutriStem® XF Supplement Mix to 500 mL of MSC NutriStem® XF Basal Medium.
  • Store complete MSC NutriStem® XF Medium at 2 to 8°C protected from light for up to 30 days.
Legal A Drug Master File (DMF) for MSC NutriStem® XF Medium is available.



Clinical Trials and Applications

  1. B Mrozikiewicz-Rakowska et al. Allogenic Adipose-Derived Stem Cells in Diabetic Foot Ulcer Treatment: Clinical Effectiveness, Safety, Survival in the Wound Site, and Proteomic Impact. International Journal of Molecular Sciences. 2023; 24(2):1472.
  2. J. B. Kaczynski and J. K. Rzepka, Endometrial regeneration in Asherman's syndrome and endometrial atrophy using Wharton’s jelly-derived mesenchymal stem cells. Ginekologia Polska, 2022
  3. E. Atanasova, et al. Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients. Stem Cell Res Ther, 2022.
  4. G. C. Blitzer, et al. A Pilot Study to Assess the Salivary Gland Regenerative Potential of Bone Marrow Mesenchymal Stromal Cells from Treated Head and Neck Cancer Patients. stem cell research & therapy, 2021, DOI:10.21203/
  5. Y. Matsuo, et al. Isolation of adipose tissue-derived stem cells by direct membrane migration and expansion for clinical application. Human Cell (2021).
  6. T. Iwanaka, et al. A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment. Stem Cell Res Ther 11, 134 (2020).
  7. V.T. Hoang, et al. Expansion of Human Mesenchymal Stromal/Stem Cells Using Standardized Xeno-Free, Serum-Free Culture Condition blood,Volume 134, Issue Supplement_1, November 13 2019,
  8. C. Bozkurt, et al. The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience tjh, 2019, 2019.0090 ;36:186-192
  9. D. Ben-David, et al. Autologous cell-coated particles for the treatment of segmental bone defects-a new cell therapy approach Journal of Orthopaedic Surgery and Research, volume 14, Article number: 198 (2019)
  10. L.A McIntyre et. al. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. American Journal of Respiratory and Critical Care Medicine, Vol. 197, No. 3, 2018
  11. K. Schlosser et al. Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients. Critical Care Medicine, doi: 10.1097/CCM.0000000000003657

Extracellular Vesicles and Exosomes

  1. R. Kou et al., Exosome-shuttled FTO from BM-MSCs contributes to cancer malignancy and chemoresistance in acute myeloid leukemia by inducing m6A-demethylation: A nano-based investigation. Environmental Research, 2023
  2. C. Pezzana et al. Biomaterial-embedded extracellular vesicles improve recovery of the dysfunctional myocardium. Biomaterials, 2022
  3. M. Wolf et al. A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation. J Extracell Vesicles. 2022
  4. L. Xiang, et. al. Exosomes from human umbilical cord mesenchymal stem cells inhibit ROS production and cell apoptosis in human articular chondrocytes via the miR-100-5p/NOX4 axis. July 2021, Cell Biology International.
  5. T. Lyu, et. al. Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4. Exp Hematol Oncol 10, 24 (2021).
  6. M. A. Skylar-Scott, et al. Biomanufacturing oforgan-specific tissues withhigh cellular density andembedded vascular channels. Sci. Adv. 2019.
  7. Y. Li, et al. Mesenchymal Stem Cells and Acelluar Products Attenuate Murine Induced Colitis. Stem Cell Research & Therapy. 03 Sep, 2020 DOI:10.21203/
  8. K. Narbute, et al. Time‑Dependent Memory and Gait Improvement by Intranasally‑Administered Extracellular Vesicles in Parkinson’s Disease Model Rats. Cellular and Molecular Neurobiology, 5 May 2020
  9. X. Wang, et al. Exosomes influence the behavior of human mesenchymal stem cells on titanium surfaces Biomaterials, 24 October 2019,
  10. J.W Li et al. Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5pEuropean Journal of Pharmacology, 2019
  11. Z. Zhu et al. Exosomes derived from human umbilical cord mesenchymal stem cells accelerate growth of VK2 vaginal epithelial cells through MicroRNAs in vitro. Human Reproduction, dey344,, 2018
  12. T.C. Peak et al. Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells. Biochemical and Biophysical Research Communications, Volume 499, Issue 4, 23 May 2018, Pages 1004-1010
  13. A. Jarmalavičiūtė et al., Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine–induced apoptosis. Cytotherapy, 2015
  14. U Pivoraitė et. al., Exosomes from Human Dental Pulp Stem Cells Suppress Carrageenan-Induced Acute Inflammation in Mice. Inflammation, April 2015
  15. K. Narbute et al. Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improve Motor Symptoms and Normalize Tyrosine Hydroxylase Expression in the Substantia Nigra and Striatum of the 6-Hydroxydopamine-Treated Rats. STEM CELLS TRANSLATIONAL MEDICINE, pp. 1-10, 2019
  16. U. Jonavičė et al. Extracellular vesicles can act as a potent immunomodulators of human microglial cells. Journal of Tissue Engineering and Regenerative Medicine, 2019
  17. S. Bobis-Wozowicz et al. Diverse impact of xeno-free conditions on biological and regenerative properties of hUC-MSCs and their extracellular vesicles. Journal of Molecular Medicine, 2016
  18. M.Pokrywczynska et al., Transdifferentiation of Bone Marrow Mesenchymal Stem Cells into the Islet-Like Cells: the Role of Extracellular Matrix Proteins. Archivum Immunologiae et Therapiae Experimentalis, May 2015


  1. I. Szabłowska-Gadomska et al. Microbiological Aspects of Pharmaceutical Manufacturing of Adipose-Derived Stem Cell-Based Medicinal Products. Cells. 2023; 12(5):680.
  2. B. Mrozikiewicz-Rakowska et al. Allogenic Adipose-Derived Stem Cells in Diabetic Foot Ulcer Treatment: Clinical Effectiveness, Safety, Survival in the Wound Site, and Proteomic Impact. International Journal of Molecular Sciences, 2023
  3. Y. Xie et al. Promotion effect of apical tooth germ cell-conditioned medium on osteoblastic differentiation of periodontal ligament stem cells through regulating miR-146a-5p. BMC Oral Health 22, 541 (2022)
  4. M. Machour et al. Print-and-Grow within a Novel Support Material for 3D Bioprinting and Post-Printing Tissue Growth. Advanced Science, 2022
  5. V.P. Mantripragada and G.F. Muschler Improved biological performance of human cartilage-derived progenitors in platelet lysate xenofree media in comparison to fetal bovine serum media. Current Research in Translational Medicine, 2022
  6. S. Cai et al. Single-cell RNA sequencing reveals the potential mechanism of heterogeneity of immunomodulatory properties of foreskin and umbilical cord mesenchymal stromal cells. Cell & Bioscience volume 12, Article number: 115 (2022)
  7. S. Sonoda et al. Protocol to generate xenogeneic-free/serum-free human dental pulp stem cells. STAR Protocols, 2022
  8. F. Yano et al. Effects of conditioned medium obtained from human adipose-derived stem cells on skin inflammation. Regenerative Therapy, 2022
  9. Y. Tan et al.HucMSC-derived exosomes delivered BECN1 induces ferroptosis of hepatic stellate cells via regulating the xCT/GPX4 axis. Cell Death & Disease, 2022
  10. L. Souza-Moreira, et al. Poly(I:C) enhances mesenchymal stem cell control of myeloid cells from COVID-19 patients. iScience, 2022
  11. D. Murata, et al. Osteochondral regeneration of the femoral medial condyle by using a scaffold-free 3D construct of synovial membrane-derived mesenchymal stem cells in horses. BMC Vet Res, 2022.
  12. R. Vaka, et al. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury. Stem Cell Res Ther, 2022
  13. S. Landau, et al. Human-engineered auricular reconstruction (hEAR) by 3D-printed molding with human-derived auricular and costal chondrocytes and adipose-derived mesenchymal stem cells. Biofabrication, 2021.
  1. P. Vigneault, et al. Electrophysiological engineering of heart-derived cells with calcium-dependent potassium channels improves cell therapy efficacy for cardioprotection. Nat Commun, 2021.
  2. F. K. Touani, et al. Pharmacological Preconditioning Improves the Viability and Proangiogenic Paracrine Function of Hydrogel-Encapsulated Mesenchymal Stromal Cells. Stem Cells International  2021
  3. F. Mahyudin, et al. The Escalation of Osteosarcoma Stem Cells Apoptosis After the Co-Cultivation of Peripheral Blood Mononuclear Cells Sensitized with Mesenchymal Stem Cells Secretome and Colony Stimulating Factor-2 in vitro. J Blood Med. 2021.
  4. A. Tait, et al. GMP compliant isolation of mucosal epithelial cells and fibroblasts from biopsy samples for clinical tissue engineering. Sci Rep 11, 12392 (2021).
  5. A. Ścieżyńska,et. al. Influence of Hypothermic Storage Fluids on Mesenchymal Stem Cell Stability: A Comprehensive Review and Personal Experience. Cells 2021,
  6. I. Nikolits, Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells. Cells, 2021,10, 886.
  7. S. Bhat, et al. Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions. Sci Rep 11, 3403 (2021).
  8. M.G. Svahn, ALLOGENEIC COMPOSITION. US Patent App. 16/969,558, 2021
  9. G. G. Ying Chiew, et al. Optimizing Large-scale Expansion of Mesenchymal Stem Cells in 3D Tide Motion Bioreactors. Esco Aster poster publication, 2019.
  10. N. Aydoğdu, et al. Isolation, Culture, Cryopreservation, and Preparation of Skin-Derived Fibroblasts as a Final Cellular Product Under Good Manufacturing Practice–Compliant Conditions. Methods in Molecular Biology. (2020) Springer, New York, NY.
  11. Jeriha J., et al. mRNA-Based Reprogramming Under Xeno-Free and Feeder-Free Conditions. Methods in Molecular Biology, 22 June 2020. DOI
  12. S. Suresh,et al. A nanocomposite hydrogel delivery system for mesenchymal stromal cell secretome. Stem Cell Res Ther 11, 205 (2020).
  13. V.Alonso-Camino & B.Mirsch, Development of standard protocol for the cGMP production of human mesenchymal stem/stromal cells from different source tissues. Cytotherapy Volume 22, Issue 5, Supplement, May 2020, Page SS65-S66,
  14. A. López Fernández, et al. Successful scale up expansion of Wharton's jelly mesenchymal stromal cells in different commercial xeno-free and serum-free media. Cytotherapy Volume 22, Issue 5, Supplement, May 2020, Page S94,
  15. B. Brinkhof, et al. ALCAM (CD166) as a gene expression marker for human mesenchymal stromal cell characterisation. Gene: X 14 March 2020, 100031,
  16. Guan, S., et al. Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model. EJNMMI Res 10, 13 (2020).
  17. S. Mount et. al. Physiologic expansion of human heartderived cells enhances therapeutic repair of injured myocardium. Stem Cell Research & Therapy (2019) 10:316
  18. S. R. Cohen, et al. Cellular Optimization of Nanofat: Comparison of Two Nanofat Processing Devices in Terms of Cell Count and Viability Aesthetic Surgery Journal Open Forum, Published: 30 September 2019
  19. D. Boruczkowski, et al. Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study  Hindawi Stem Cells International Volume 2019, Article ID 7402151, 13 pages,
  20. G.Sagaradze, et al. Conditioned Medium from Human Mesenchymal Stromal Cells: Towards the Clinical Translation Int.J.Mol.Sci. 2019, 20, 1656; doi:10.3390/ijms20071656
  21. M.Valitsky et al. Cerebrospinal Fluid (CSF) Exchange with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Experimental Autoimmune Encephalomyelitis Int.J.Mol. Sci., 2019, 20(7),1793;
  25. V. Alonso-Camino and B. Mirsch, Rapid expansion of Mesenchymal Stem/Stromal Cells using optimized media supplemented with human platelet lysate PLTMax® or PLTGold®, suitable for cGMP expansion at large scale. Cytotherapy, Volume 21, Issue 5, Supplement, May 2019, Page S85
  26. S. Pang et al. DISSECTING THE MOLECULAR PATHWAYS OF APOPTOSIS IN MESENCHYMAL STROMAL CELL THERAPY. Cytotherapy, Volume 21, Issue 5, Supplement, May 2019, Page S85
  27. M. Valitsky et al. Cerebrospinal Fluid (CSF) Exchange with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Experimental Autoimmune Encephalomyelitis. Int. J. Mol. Sci. 2019, 20(7), 1793;
  28. A. Yamasaki et al. Osteochondral regeneration using constructs of mesenchymal stem cells made by bio three‐dimensional printing in mini‐pigs. Journal of Orthopaedic Research, 2018
  29. Vu N.B., Le P.TB., Truong N.C., Van Pham P. (2018) Off-the-Shelf Mesenchymal Stem Cell Technology. In: Pham P. (eds) Stem Cell Drugs - A New Generation of Biopharmaceuticals. Stem Cells in Clinical Applications. Springer, Cham
  30. J.K. Ledwon et al. Osteogenic Differentiation Of Msc As A Model Study Of The Postnatal Progressive Crouzon Syndrome. Plastic and Reconstructive Surgery - Global Open. 6(4S):116, APR 2018
  31. D.Lisini et al. Adipose tissue-derived mesenchymal stromal cells for clinical application: An efficient isolation approach. Current Research in Translational Medicine,
  32. S. Khan et al. cGMP-Compatible Large-Scale Production of Mesenchymal Stem Cells (MSCs) In Xeno- and Serum-Free Media for Allogeneic Cell Therapies. Cytotherapy,Volume 20, Issue 5, Supplement, Page S42, 2018
  33. A.C. Volz and P.J. Kluger, Completely serum-free and chemically defined adipocyte development and maintenance.Cytotheraoy, April 2018 Volume 20, Issue 4, Pages 576–588
  34. C. Elseberg et al. The Challenge of Human Mesenchymal Stromal Cell Expansion: Current and Prospective Answers. New Insights into Cell Culture Technology, Dr. Sivakumar Joghi Thatha Gowder (Ed.), InTech.
  35. C. Ceccaldi et al. Optimization of Injectable Thermosensitive Scaffolds with Enhanced Mechanical Properties for Cell Therapy. Macromolecular Bioscience, 2017
  36. D. Boruczkowski et al.Third-party Wharton’s jelly mesenchymal stem cells for treatment of steroid-resistant acute and chronic graft-versus-host disease: a report of 10 cases. Turkish Journal of Biology, 40: 493-500, 2016
  37. Jianxia H. et al. Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes. Experimental and Therapeutic Medicine, Volume 12 Issue 3, 2016
  38. L. Berger et al. Tumor Specific Recruitment and Reprogramming of Mesenchymal Stem Cells in TumorigenesisSTEM CELLS Volume 34, Issue 4, Version of Record online: 31 DEC 2015
  39. K.Y. Tan et al. Serum-free media formulations are cell line–specific and require optimization for microcarrier culture. Cytotherapy, 2015 
  40. Cai, Zhen, et al. Chondrogenesis of Human Adipose-Derived Stem Cells by In Vivo Co-graft with Auricular Chondrocytes from Microtia. Aesthetic plastic surgery 39.3 (2015): 431-439.
  41. S.H. Mei, et al. Isolation and large-scale expansion of bone marrow-derived mesenchymal stem cells with serum-free media under GMP-compliance. Cytotherapy, Volume 16, Issue 4, Supplement , Page S111, April 2014
  42. Mira Genser-Nir et al. Toward a serum-free, xeno-free culture system for optimal growth and expansion of hMSC suited to therapeutic applications. BMC Proc. 2013; 7(Suppl 6): P6.
  43. McVey, Mark John, et al. Microparticles as biomarkers of lung disease-enumeration in biological fluids using lipid bilayer microspheres. American Journal of Physiology-Lung Cellular and Molecular Physiology (2016): ajplung-00369.
  44. Y. Lopez, et al. Identification of Optimal Conditions For Generating MSCs For Preclinical Testing: Comparison of Three Commercial Serum-Free Media And Low-Serum Growth Medium. From 18th ISCT Annual Meeting, Seattle, USA, 2012.
  45. R. D. Foster et al. GorodetskyFibrin microbeads loaded with mesenchymal cells support their long-term survival while sealed at room temperature.Tissue Eng Part C Methods2011TISSUE ENGINEERING: Part C, Volume 17, Number 7, 2011


Certificate of Analysis

Certificates of Analysis (COA's) describe quality control data for specific product lots.

COA's can be downloaded from Sartorius's Certificates Portal.

For certificates issued before November 15, 2021, please enter below the product lot number and click search.
If your search does not return any results, please contact us for assistance.


Customer Reviews (4)

Quality and consistency cellsReview by Prof. Avner Yayon
I must say that as a cell biologist I am very impressed from the quality and consistency of MSCs cultured in MSC NutriStem media (Posted on 12/19/2019)
my cells love it!Review by Tony
Added platelet lysate and my cells really took off and look great. (Posted on 5/22/2018)
very efficientReview by Yasmin
We found this product to be very useful for growing MSCs, especially by means of reserving their properties. (Posted on 1/16/2018)
excellentReview by Jason
outstanding performance for my MSC cells, both morphology and proliferation (Posted on 8/5/2016)

Write Your Own Review

You're reviewing: MSC NutriStem® XF Medium

How do you rate this product? *

  1 star 2 stars 3 stars 4 stars 5 stars

You may also be interested in the following product(s)